臨床試驗

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

NCT：NCT02876042 · COMPLETED

NCT IDNCT02876042

狀態COMPLETED

開始日期2017-03-23

完成時間2025-11-03

SponsorCVRx, Inc. (INDUSTRY)

First posted2016-08-23

Last updated2026-09-11

簡要摘要

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。